Applied BioCode Statistics

Total Valuation

Applied BioCode has a market cap or net worth of TWD 1.99 billion. The enterprise value is 1.16 billion.

Market Cap	1.99B
Enterprise Value	1.16B

Important Dates

The next estimated earnings date is Monday, May 12, 2025.

Earnings Date	May 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Applied BioCode has 102.79 million shares outstanding. The number of shares has increased by 10.82% in one year.

Current Share Class	102.79M
Shares Outstanding	102.79M
Shares Change (YoY)	+10.82%
Shares Change (QoQ)	+7.24%
Owned by Insiders (%)	0.22%
Owned by Institutions (%)	4.74%
Float	86.22M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.81
PB Ratio	2.27
P/TBV Ratio	2.27
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-4.43
EV / Sales	3.37
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-5.37

Financial Position

The company has a current ratio of 8.51, with a Debt / Equity ratio of 0.02.

Current Ratio	8.51
Quick Ratio	6.95
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	-0.09
Interest Coverage	-194.75

Financial Efficiency

Return on equity (ROE) is -33.87% and return on invested capital (ROIC) is -21.80%.

Return on Equity (ROE)	-33.87%
Return on Assets (ROA)	-15.73%
Return on Invested Capital (ROIC)	-21.80%
Return on Capital Employed (ROCE)	-25.61%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.31
Inventory Turnover	0.76

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +2.38% in the last 52 weeks. The beta is 0.51, so Applied BioCode's price volatility has been lower than the market average.

Beta (5Y)	0.51
52-Week Price Change	+2.38%
50-Day Moving Average	20.77
200-Day Moving Average	22.38
Relative Strength Index (RSI)	47.05
Average Volume (20 Days)	110,635

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Applied BioCode had revenue of TWD 343.07 million and -260.81 million in losses. Loss per share was -2.88.

Revenue	343.07M
Gross Profit	204.00M
Operating Income	-277.91M
Pretax Income	-260.78M
Net Income	-260.81M
EBITDA	-231.33M
EBIT	-277.91M
Loss Per Share	-2.88

Full Income Statement

Balance Sheet

The company has 857.49 million in cash and 19.52 million in debt, giving a net cash position of 837.96 million or 8.15 per share.

Cash & Cash Equivalents	857.49M
Total Debt	19.52M
Net Cash	837.96M
Net Cash Per Share	8.15
Equity (Book Value)	878.83M
Book Value Per Share	8.55
Working Capital	974.46M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -207.74 million and capital expenditures -7.38 million, giving a free cash flow of -215.12 million.

Operating Cash Flow	-207.74M
Capital Expenditures	-7.38M
Free Cash Flow	-215.12M
FCF Per Share	-2.09

Full Cash Flow Statement

Margins

Gross margin is 59.46%, with operating and profit margins of -81.01% and -76.02%.

Gross Margin	59.46%
Operating Margin	-81.01%
Pretax Margin	-76.01%
Profit Margin	-76.02%
EBITDA Margin	-67.43%
EBIT Margin	-81.01%
FCF Margin	n/a

Dividends & Yields

Applied BioCode does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.82%
Shareholder Yield	-10.82%
Earnings Yield	-13.08%
FCF Yield	-10.79%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Applied BioCode has an Altman Z-Score of 3.43.

Altman Z-Score	3.43
Piotroski F-Score	n/a